Can the effectiveness of hypertension management be improved?

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 6, 2013, Pages 689-695

  Ruilope, Luis M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

ambulatory blood pressure monitoring; antihypertensive; effectiveness; efficacy; hypertension

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ANTIHYPERTENSIVE AGENT; AR 9281; AZILSARTAN MEDOXOMIL; BENDROFLUMETHIAZIDE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; COBINAMIDE; DAGLUTRIL; HYDROCHLOROTHIAZIDE; ILEPATRIL; INDAPAMIDE; LCI 699; LOSARTAN; NAPROXCINOD; PL 3994; PMD 3117; PS 433540; QGC 001; TELMISARTAN; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE THERAPY; CLINICAL EFFECTIVENESS; DRUG COST; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MASKED HYPERTENSION; ORTHOSTATIC HYPOTENSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRACTICE GUIDELINE; REVIEW; VACCINATION; WHITE COAT HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84878844094     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.13.18     Document Type: Review

References (44)

1. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371(9623), 1513-1518 (2008).
2. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 360(9343), 1347-1360 (2002).
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903-1913 (2002).
4. Perera GA. Hypertensive vascular disease; description and natural history. J. Chronic Dis. 1(1), 33-42 (1955).
5. Ruilope LM. Current challenges in the clinical management of hypertension. Nat. Rev. Cardiol. 9(5), 267-275 (2012).
6. Erdine S. How well is hypertension controlled in Europe? ESH Scientific Newsletter 12(3), 5-6 (2011).
7. Lindholm LH. The problem of uncontrolled hypertension. J. Hum. Hypertens. 16(Suppl. 3), S3-S8 (2002).
8. Basile J. The importance of prompt blood pressure control. J. Clin. Hypertens. (Greenwich) 10(1 Suppl. 1), 13-19 (2008).
9. Berlowitz DR, Franklin S. The clock is ticking: the case for achieving more rapid control of hypertension. J. Clin. Hypertens. (Greenwich) 12(5), 323-327 (2010).
10. Mancia G, De Backer G, Dominiczak A et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25(9), 1751-1762 (2007).
11. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305(9), 913-922 (2011).
12. Mancia G, Grassi G. Management of essential hypertension. Br. Med. Bull. 94, 189-199
13. Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121-2158 (2009).
14. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J. Hypertens. 27(5), 923-934 (2009).
15. NICE. Hypertension: the clinical management of primary hypertension in adults. Update of clinical guidelines 18 and 34. London College of Physicians, UK (2011).
16. Beckett NS, Peters R, Fletcher AE et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 358(18), 1887-1898 (2008).
17. Aronow WS, Fleg JL, Pepine CJ et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J. Am. Coll. Cardiol. 57(20), 2037-2114 (2011).
18. Barengo NC, Tuomilehto JO. Blood pressure treatment target in patients with diabetes mellitus-current evidence. Ann. Med. 44(Suppl. 1), S36-S42 (2012).
19. McBrien K, Rabi DM, Campbell N et al. Intensive and standard blood pressure targets in patients with Type 2 diabetes mellitus: systematic review and meta-analysis. Arch. Intern. Med. 172(17), 1296-1303 (2012).
20. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 36(Suppl. 1), S11-S66 (2013).
21. O'Brien E. Twenty-four-hour ambulatory blood pressure measurement in clinical practice and research: a critical review of a technique in need of implementation. J. Intern. Med. 269(5), 478-495 (2011).
22. Celis H, Den Hond E, Staessen JA. Self-measurement of blood pressure at home in the management of hypertension. Clin. Med. Res. 3(1), 19-26 (2005).
23. Puig JG, Ruilope LM, Ortega R. Antihypertensive treatment efficacy in Type II diabetes mellitus. Dissociation between casual and 24-hour ambulatory blood pressure. Spanish Multicenter Study Group. Hypertension 26(6 Pt 2), 1093-1099 (1995).
24. Banegas JR, Messerli FH, Waeber B et al. Discrepancies between office and ambulatory blood pressure: clinical implications. Am. J. Med. 122(12), 1136-1141 (2009).
25. Zanchetti A, Mancia G, Black HR et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J. Hypertens. 27(4), 673-679 (2009).
26. Ruilope LM, Bakris GL. Therapeutic Strategies in Hypertension. Clinical Publishing, Oxford, UK (2006).
27. de la Sierra A, Segura J, Banegas JR et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57(5), 898-902 (2011).
28. DiNicolantonio JJ. Hydrochlorothiazide: is it a wise choice? Expert Opin. Pharmacother. 13(6), 807-814 (2012).
29. Ernst ME, Carter BL, Goerdt CJ et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47(3), 352-358 (2006).
30. Kountz DS, Goldman A, Mikhail J, Ezer M. Chlorthalidone: the forgotten diuretic. Postgrad. Med. 124(1), 60-66 (2012).
31. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 57(4), 689-694 (2011).
32. Paulis L, Steckelings UM, Unger T. Key advances in antihypertensive treatment. Nat. Rev. Cardiol. 9(5), 276-285 (2012).
33. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet 380(9841), 591-600 (2012).
34. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375(9722), 1255-1266 (2010).
35. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J. Pharmacol. Exp. Ther. 336(3), 801-808 (2011).
36. Bakris GL, Sica D, Weber M et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J. Clin. Hypertens. (Greenwich) 13(2), 81-88 (2011).
37. Sica D, White WB, Weber MA et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J. Clin. Hypertens. (Greenwich) 13(7), 467-472 (2011).
38. White WB, Weber MA, Sica D et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 57(3), 413-420 (2011).
39. Bonner G, Bakris GL, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensinconverting enzyme inhibitor ramipril. J. Hum. Hypertens. doi:10.1038/jhh.2013.6 (2013) (Epub ahead of print).
40. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376(9756), 1903-1909 (2010).
41. Ruilope LM, Volpe M. The case for blood pressure control in risk groups. Int. J. Clin. Pract. 58(9), 844-849 (2004).
42. Rydén L, Waeber B, Ruilope LM et al. The management of the Type 2 diabetic patient with hypertension-too late and too little: suggested improvements. Blood Press. 17(5-6), 250-259 (2008).
43. Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 59(2), 331-338 (2012).
44. Taylor JG, Bisognano JD. Baroreflex stimulation in antihypertensive treatment. Curr. Hypertens. Rep. 12(3), 176-181 (2010).